

REMARKSELECTION REQUIREMENT

In response to the restriction requirement mailed November 30, 2007, applicants hereby elect the Group I invention, i.e., claims 1-6 (drawn to a process for preparing (+)-duloxetine or an acid addition salt thereof by resolving racemic ( $\pm$ )duloxetine with a chiral acid).

This election is made without traverse.

Accordingly, Applicants have cancelled claims 7-17, directed to the non-elected subject matter of the Groups II and III inventions.

Applicants expressly reserve their rights to file one or more divisional application(s) directed to the non-elected subject matter claiming the benefits afforded by 35 USC 119, 120 and 121.

Applicants have additionally amended claims 18-20 so as to depend from independent claim 1 of the Group I invention. As this makes these claims (together with claims 21 and 22) linking claims, Applicants submit they should be examined with the Group I invention.

As ( $\pm$ )duloxetine is a specific compound, there appears to be no election of a particular species to be made.

Therefore, withdrawal of the Species Requirement is warranted.

Reconsideration and withdrawal of the Species Requirement are respectfully requested.

If any fee is necessary, it may be charged to the undersigned's deposit account number 19-4375.

TPP/mat  
Attorney Docket No.: TPP 31770

Respectfully submitted,



Thomas P. Pavelko  
Registration No. 31,689

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.  
1615 L Street, N.W., Suite 850  
Washington, D.C. 20036  
Telephone: (202) 785-0100  
Facsimile: (202) 408-5200 or (202) 408-5088

Date: December 28, 2007